Aarti Pharmalabs (NSE:AARTIPHARM) Tax Provision: ₹-622 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
50 GF Score
Price ₹717.40
GF Value ₹644.61
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Tax Provision?

Aarti Pharmalabs NSE:AARTIPHARM -0.12% 50 Tax Provision is ₹-622 Mil as of Mar. 2026. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 50/100 and a GF Value™ of ₹644.61 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Aarti Pharmalabs's tax provision for the three months ended in Mar. 2026 was ₹-206 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-622 Mil.

Aarti Pharmalabs Tax Provision Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Tax Provision Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Provision
Get a 7-Day Free Trial -331.29 -672.81 -835.90 -882.85 -582.14

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -262.79 -159.53 -107.69 -149.13 -205.55
NSE:AARTIPHARM
50GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-622 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ₹-622 Mil mean?
Aarti Pharmalabs (NSE:AARTIPHARM) has a Tax Provision of ₹-622 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Aarti Pharmalabs and its competitors.
Is Aarti Pharmalabs' Tax Provision too high?
Aarti Pharmalabs' current Tax Provision is ₹-622 Mil. Overall, Aarti Pharmalabs has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Tax Provision compare to ZTS and UTHR?
Aarti Pharmalabs' Tax Provision of ₹-622 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Drug Manufacturers company?
A good Tax Provision depends on the Drug Manufacturers industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Aarti Pharmalabs and its competitors. Aarti Pharmalabs's current Tax Provision is ₹-622 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹644.61, compared to a current price of ₹717.40 — trading 11.3% above its estimated fair value. The current Tax Provision is ₹-622 Mil. Aarti Pharmalabs' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Tax Provision is ₹-622 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹717.40 is trading 11.3% above its estimated GF Value™ of ₹644.61. GuruFocus considers Aarti Pharmalabs to be Modestly Overvalued.

Key valuation signals for NSE:AARTIPHARM:

  • Tax Provision: ₹-622 Mil
  • GF Value™: ₹644.61 vs. price of ₹717.40 (11.3% above fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
50GF Score

Get the complete analysis for NSE:AARTIPHARM

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹717.40
Price
₹644.61
GF Value